Diagnostic gene sequencing panels: from design to report—a technical standard of the American College of Medical Genetics and Genomics (ACMG)

Gene sequencing panels are a powerful diagnostic tool for many clinical presentations associated with genetic disorders. Advances in DNA sequencing technology have made gene panels more economical, flexible, and efficient. Because the genes included on gene panels vary widely between laboratories in gene content (e.g., number, reason for inclusion, evidence level for gene–disease association) and technical completeness (e.g., depth of coverage), standards that address technical and clinical aspects of gene panels are needed. This document serves as a technical standard for laboratories designing, offering, and reporting gene panel testing. Although these principles can apply to multiple indications for genetic testing, the primary focus is on diagnostic gene panels (as opposed to carrier screening or predictive testing) with emphasis on technical considerations for the specific genes being tested. This technical standard specifically addresses the impact of gene panel content on clinical sensitivity, specificity, and validity—in the context of gene evidence for contribution to and strength of evidence for gene–disease association—as well as technical considerations such as sequencing limitations, presence of pseudogenes/gene families, mosaicism, transcript choice, detection of copy-number variants, reporting, and disclosure of assay limitations.

[1]  W. Jhang,et al.  Cardiac Manifestations and Associations with Gene Mutations in Patients Diagnosed with RASopathies , 2016, Pediatric Cardiology.

[2]  P. Bauer,et al.  Prion mutation D178N with highly variable disease onset and phenotype , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[3]  Joshua L. Deignan,et al.  ACMG clinical laboratory standards for next-generation sequencing , 2013, Genetics in Medicine.

[4]  O. Klein,et al.  A review of craniofacial and dental findings of the RASopathies. , 2017, Orthodontics & craniofacial research.

[5]  T. Foroud,et al.  Neurology Individualized Medicine: When to Use Next-Generation Sequencing Panels. , 2017, Mayo Clinic proceedings.

[6]  Carolyn Y. Ho,et al.  Hypertrophic Cardiomyopathy Overview , 2014 .

[7]  Carol J. Bult,et al.  The Mouseion at the JAXlibrary , 2022 .

[8]  Yiping Shen,et al.  Evaluation of copy number variant detection from panel‐based next‐generation sequencing data , 2018, Molecular genetics & genomic medicine.

[9]  E. Puffenberger,et al.  Genetics, medicine, and the Plain people. , 2009, Annual review of genomics and human genetics.

[10]  K. Helbig,et al.  Classification of Genes: Standardized Clinical Validity Assessment of Gene–Disease Associations Aids Diagnostic Exome Analysis and Reclassifications , 2017, Human mutation.

[11]  Bale,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[12]  Matthew S. Lebo,et al.  Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: expanded panels offer limited additional sensitivity , 2015, Genetics in Medicine.

[13]  Binay Panda,et al.  Validation of copy number variation analysis for next-generation sequencing diagnostics , 2017, European Journal of Human Genetics.

[14]  Marjolein Kriek,et al.  Next‐Generation Diagnostics: Gene Panel, Exome, or Whole Genome? , 2015, Human mutation.

[15]  D. Cattan,et al.  [Familial Mediterranean fever]. , 2002, La Revue du praticien.

[16]  R. Pagon,et al.  Hereditary Hearing Loss and Deafness Overview -- GeneReviews® , 2020 .

[17]  J. Michael Cherry,et al.  Evaluating the clinical validity of gene-disease associations: an evidence-based framework developed by the Clinical Genome Resource , 2017, bioRxiv.

[18]  S. Daiger,et al.  Nonsyndromic Retinitis Pigmentosa Overview , 2017 .

[19]  S. Bale,et al.  Assessing copy number from exome sequencing and exome array CGH based on CNV spectrum in a large clinical cohort , 2014, Genetics in Medicine.

[20]  Birgit Funke,et al.  Development and Validation of Targeted Next-Generation Sequencing Panels for Detection of Germline Variants in Inherited Diseases. , 2017, Archives of pathology & laboratory medicine.

[21]  Matthew Ferber,et al.  Evaluation for Genetic Disorders in the Absence of a Clinical Indication for Testing: Elective Genomic Testing. , 2019, The Journal of molecular diagnostics : JMD.

[22]  Hanxin Lin,et al.  Clinical Validation of Copy Number Variant Detection from Targeted Next-Generation Sequencing Panels. , 2017, The Journal of molecular diagnostics : JMD.

[23]  Nazneen Rahman,et al.  CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. , 2004, American journal of human genetics.

[24]  H. Reddi,et al.  Clinical utility of a 377 gene custom next-generation sequencing epilepsy panel , 2017, Journal of Genetics.

[25]  Birgit Funke,et al.  Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing , 2016, Genetics in Medicine.